These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15127424)

  • 1. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.
    Dakin H; Devlin N; Feng Y; Rice N; O'Neill P; Parkin D
    Health Econ; 2015 Oct; 24(10):1256-1271. PubMed ID: 25251336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stated preference binary choice experiment to explore NICE decision making.
    Tappenden P; Brazier J; Ratcliffe J; Chilcott J
    Pharmacoeconomics; 2007; 25(8):685-93. PubMed ID: 17640110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
    Dakin HA; Devlin NJ; Odeyemi IA
    Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for cost effectiveness thresholds in the NHS.
    Appleby J; Devlin N; Parkin D; Buxton M; Chalkidou K
    Health Policy; 2009 Aug; 91(3):239-45. PubMed ID: 19168255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
    Getsios D; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness modeling for neuropathic pain treatments: investigating the relative importance of parameters using an open-source model.
    Hirst M; Bending MW; Baio G; Yesufu-Udechuku A; Dunlop WCN
    J Med Econ; 2018 Sep; 21(9):930-935. PubMed ID: 29882452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness comparison of the NICE 2015 and WHO 2013 diagnostic criteria for women with gestational diabetes with and without risk factors.
    Jacklin PB; Maresh MJ; Patterson CC; Stanley KP; Dornhorst A; Burman-Roy S; Bilous RW
    BMJ Open; 2017 Aug; 7(8):e016621. PubMed ID: 28801424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE's social value judgements about equity in health and health care.
    Shah KK; Cookson R; Culyer AJ; Littlejohns P
    Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.